Publications
This page is a selection, not a complete bibliography. It holds my five most recent publications, my co-edited book, and the nine most-cited papers I have been involved in. The complete record of 60+ publications lives on Google Scholar and ORCiD.
Recent publications
Published in BMC Medical Informatics and Decision Making, September 2026
A design for a research environment that lets analysts work on sensitive patient data without the data leaving the custodian, while keeping it findable, accessible, interoperable and reusable. The tension it addresses runs through much of health economics: the richest data for modelling is usually the hardest to share.
Citation: Müller M, Geisler BP, Shamas S, von Bomhard N, Hoster E, Pfirrmann M, Mansmann U (2026). "FAIR by design (TRACE): A Trusted Research Access & Collaboration Environment." BMC Med Inform Decis Mak. doi:10.1186/s12911-026-03840-3
Published in World Allergy Organization Journal, August 2026
How many more patients would qualify for asthma biologics if the eligibility criteria were widened, and what that would cost. The question is the one that drives my doctoral work in precision oncology: when a targeted therapy is expensive, where the eligibility line is drawn largely determines the budget.
Citation: Yang F, Geisler BP, d’Ancona G, Lee B, Jackson DJ, Bloom CI (2026). "Prevalence and cost implications of broadening asthma biologic eligibility criteria." World Allergy Organ J. doi:10.1016/j.waojou.2026.101449
Published in Nephrology Dialysis Transplantation, July 2026
A comparison of two treatments for the syndrome of inappropriate antidiuresis in hospitalized patients. It continues a line of work with the same group on urea as an inexpensive alternative to tolvaptan, and belongs to the evidence-based internal medicine strand of my work rather than the modelling one.
Citation: Heller M, Marx K, Hoffmann U, Rebettge J, Bader F, Fenves AZ, Geisler BP, Wendt R (2026). "Urea versus tolvaptan for hospitalized patients with SIAD." Nephrol Dial Transplant. doi:10.1093/ndt/gfag165
Published in Circulation Reports, July 2026
An economic evaluation of leadless pacemakers with atrioventricular synchrony, carried out for the Japanese payer setting. It is one of a long series of medical device evaluations I have worked on, and a reminder that a device judged good value in one health system is not automatically good value in another.
Citation: Satomi K, Soejima K, Kusano K, Myung JE, Tanaka Y, Ryschon AM, Geisler BP, Ikeno F, Pietzsch JB (2026). "Cost-Effectiveness of Atrioventricular Synchronous Leadless Pacing in Patients With Atrioventricular Block." Circ Rep. doi:10.1253/circrep.cr-26-0090
Published in PharmacoEconomics, June 2026
When the evidence does not settle how a decision model should be structured, modellers ask experts. This review, written with colleagues at the University of Oslo, takes stock of how that is actually being done. It is the methodological centre of my doctoral work: a model’s structure shapes its results at least as much as the parameters fed into it.
Citation: Geisler BP, Holmboe F, Starinieri I, Aas E (2026). "Applications of Structural Expert Elicitations for Economic Evaluations: A Systematic Review Update." Pharmacoeconomics. doi:10.1007/s40273-026-01628-x
Books
Published in Oxford University Press, 2026
A co-edited volume in the 50 Studies Every Doctor Should Know series. Each chapter takes one landmark study in hospital medicine and sets out what it asked, what it found, and what it does and does not settle at the bedside. It grew out of a decade of teaching residents at Massachusetts General Hospital and Harvard Medical School.
Citation: Geisler BP, Greenwald JL, Tran H, editors (2026). 50 Studies Every Hospitalist Should Know. Oxford University Press.
Other selected publications
Published in Journal of the American College of Cardiology, September 2012
My most cited paper. An early economic evaluation of renal denervation, published while the technique was still expanding, projecting the long-term cardiovascular consequences and costs of lowering blood pressure in patients whose hypertension resisted drug treatment. It became a reference point in later health technology assessments of the procedure.
Citation: Geisler BP, Egan BM, Cohen JT, Garner AM, Akehurst RL, Esler MD, Pietzsch JB (2012). "Cost-Effectiveness and Clinical Effectiveness of Catheter-Based Renal Denervation for Resistant Hypertension." J Am Coll Cardiol 60(14):1271-1277. doi:10.1016/j.jacc.2012.07.029
Published in The American Journal of Sports Medicine, March 2018
A comparison of three ways of managing a medial meniscus root tear, followed out far enough for the downstream osteoarthritis, knee replacements and costs to appear. The surgical choice looks different once the consequences are counted over a lifetime rather than over a recovery period.
Citation: Faucett SC, Geisler BP, Chahla J, Krych AJ, Kurzweil PR, Garner AM, Liu S, LaPrade RF, Pietzsch JB (2018). "Meniscus Root Repair vs Meniscectomy or Nonoperative Management to Prevent Knee Osteoarthritis After Medial Meniscus Root Tears: Clinical and Economic Effectiveness." Am J Sports Med. doi:10.1177/0363546518755754
Published in Journal for ImmunoTherapy of Cancer, February 2015
A case of acute cardiomyopathy in a patient receiving ipilimumab, reported before cardiac toxicity from immune checkpoint blockade was widely recognised. I later contributed to the international registry study of checkpoint inhibitor myocarditis, which examined the same problem across several hundred cases rather than one.
Citation: Geisler BP, Raad RA, Esaian D, Sharon E, Schwartz DR (2015). "Apical ballooning and cardiomyopathy in a melanoma patient treated with ipilimumab: a case of takotsubo-like syndrome." J Immunother Cancer 3:4. doi:10.1186/s40425-015-0048-2
Published in PLOS ONE, September 2011
A national picture of how often US emergency departments placed patients under observation rather than admitting or discharging them, and how that shifted across the decade. Observation status sits awkwardly between outpatient and inpatient care, with real consequences for what patients are billed.
Citation: Venkatesh AK, Geisler BP, Gibson Chambers JJ, Baugh CW, Bohan JS, Schuur JD (2011). "Use of Observation Care in US Emergency Departments, 2001 to 2008." PLoS One 6(9):e24326. doi:10.1371/journal.pone.0024326
Published in Value in Health, July 2008
Quality-of-life weights for heart failure health states, defined by New York Heart Association class and number of rehospitalisations. Cost-effectiveness models need such numbers as inputs and rarely generate them, which is why this paper has mostly been cited by later heart failure models drawing on its estimates.
Citation: Göhler A, Geisler BP, Manne JM, Kosiborod M, Zhang Z, Weintraub WS, Spertus JA, Gazelle GS, Siebert U, Cohen DJ (2008). "Utility Estimates for Decision-Analytic Modeling in Chronic Heart Failure—Health States Based on New York Heart Association Classes and Number of Rehospitalizations." Value Health. doi:10.1111/j.1524-4733.2008.00425.x
Published in BMJ Open, May 2016
Whether drug-eluting balloons and stents for peripheral arterial disease earn their higher price by reducing reintervention, assessed from the perspective of the UK National Health Service.
Citation: Katsanos K, Geisler BP, Garner AM, Zayed H, Cleveland T, Pietzsch JB (2016). "Economic analysis of endovascular drug-eluting treatments for femoropopliteal artery disease in the UK." BMJ Open 6(5):e011245. doi:10.1136/bmjopen-2016-011245
Published in Catheterization and Cardiovascular Interventions, April 2014
A review of the economic evidence on endovascular treatment of peripheral arterial disease, paired with a budget impact model run for two health systems at once. Working the same question through both a US and a German payer is an early instance of a theme I keep returning to: economic evidence rarely transfers across borders unexamined.
Citation: Pietzsch JB, Geisler BP, Garner AM, Zeller T, Jaff MR (2014). "Economic analysis of endovascular interventions for femoropopliteal arterial disease: A systematic review and budget impact model for the United States and Germany." Catheter Cardiovasc Interv 84(4):546-554. doi:10.1002/ccd.25536
Published in Medicine, May 2021
Whether patients with the same conditions stay in hospital for different lengths of time depending on their race, ethnicity or socioeconomic position. Hospitals treat length of stay as an efficiency measure, which makes systematic variation across patient groups worth taking seriously.
Citation: Ghosh AK, Geisler BP, Ibrahim S (2021). "Racial/ethnic and socioeconomic variations in hospital length of stay." Medicine (Baltimore) 100(20):e25976. doi:10.1097/md.0000000000025976
Published in PharmacoEconomics, May 2011
A survey of how heart failure had been represented in decision-analytic models up to that point, and where those models diverged from one another. Reviewing modelling practice rather than clinical evidence is a recurring thread in my work, running from this paper through to the recent review of structural expert elicitation.
Citation: Goehler A, Geisler BP, Manne JM, Jahn B, Conrads-Frank A, Schnell-Inderst P, Gazelle GS, Siebert U (2011). "Decision-Analytic Models to Simulate Health Outcomes and Costs in Heart Failure: A Systematic Review." Pharmacoeconomics 29(9):753-769. doi:10.2165/11585990-000000000-00000
